Pharma Stocks Have Risk of U.S. Tariffs Priced In -- Market Talk
Argus Research Downgrades Biogen(BIIB.US) to Hold Rating
RFK Jr. to Reinstate 20% of HHS Staff Laid off After DOGE Errors
Argus Research Downgrades Biogen to Hold
Biogen Analyst Ratings
Biogen Stock Hits 52-week Low at $128 Amid Challenges
Express News | Shares of Merck Down 1%, Biogen Down 2.1%, Pfizer Down 1.7%, Eli Lilly Down 3.6% and Abbvie Down 1.3%
Express News | Shares of Some U.S. Drugmakers Down After Trump Says Pharmaceutical Sector Is 'under Review' for Tariffs
Argus Downgrades Biogen to Hold From Buy
RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $221
Pharma Stocks up on US Tariff Exemptions but Analyst Flags a $46B Import Cost Risk
RBC Trims Price Target on Biogen to $221 From $225, Keeps Outperform Rating
Express News | Biopharma Credit PLC - Receives $8.25 Million Settlement Payment From Biogen
Express News | Biogen: Phase 2 Celia Study Is Now Fully Enrolled, With a Data Readout Expected in 2026
Express News | Biogen’s Investigational Tau-Targeting Therapy Biib080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease
The "Liberation Day" of Trump's tariffs is approaching, and the pharmaceutical Industry may not be among the targets.
According to reports, President Trump of the USA is expected to announce a series of broader tariff measures on local time April 2 (Wednesday), which will not include any specific details on Pharmaceutical tariffs.
Organon Acquires Tofidence for Intravenous Infusion in US
Organon Acquires From Biogen U.S. Regulatory and Commercial Rights for Tofidence, a Biosimilar to Actemra, for Intravenous Infusion >OGN
Express News | Organon & Co - to Pay Tiered Royalties and Milestone Payments to Biogen